New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide– Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) US$ 25.06 Min. order: 1 piece ★★★★★ 4.3 (131 reviews) Sold : Login>>
CagriSema in Adults With or Without Diabetes – REDEFINE 1 & 2 • 💊 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly • 📉 –20.4% weight loss (non-diabetic) & –13.7% (T2D) US$ 28.02 Min. order: 1 piece ★★★★★ 4.9 (119 reviews) Sold : Login>>
Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis US$ 20.45 Min. order: 1 piece ★★★★★ 4.5 (203 reviews) Sold : Login>>
CagriSema Dual-Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP-1 receptor agonist), designed to influence key metabolic and appetite-regulating pathways. Current US$ 29.35 Min. order: 1 piece ★★★★★ 5.0 (147 reviews) Sold : Login>>
Structural Biophysics-Guided Computational Design of Semaglutide Analogues to Enhance GLP-1R Activation - Article (Preprint v1) by Wei Li US$ 27.12 Min. order: 1 piece ★★★★★ 4.4 (101 reviews) Sold : Login>>
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity US$ 27.83 Min. order: 1 piece ★★★★★ 4.0 (48 reviews) Sold : Login>>